Clinical Trial Update: Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports that the Phase 1/2 study evaluating SAGE-547 as adjunctive therapy for super-refractory status epilepticus has completed, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Super-refractory Status Epilepticus

Drugs mentioned

• SAGE-547 Injection

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Super-refractory Status Epilepticus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-05-03